Posted by Michael Wonder on 16 Jun 2021
TLV receives a new assignment for precision medicine and advanced therapy drugs
15 June 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, is commissioned by the government to continue the work of developing methods for health economic evaluations of precision medicines and payment models for advanced therapy drugs.
It is an opportunity for TLV to further develop several of the proposals from the previous assignment that the authority reported on 1 May, for example how uncertainty in the documentation is to be described and influence decisions.
